These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 34431250)

  • 1. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective.
    Kim GH; Kim JH; Kim PH; Chu HH; Gwon DI; Ko HK
    Korean J Radiol; 2021 Nov; 22(11):1822-1833. PubMed ID: 34431250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress.
    Brown ZJ; Hewitt DB; Pawlik TM
    Expert Opin Investig Drugs; 2022 Apr; 31(4):379-391. PubMed ID: 34788184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of locoregional therapies in the wake of systemic therapy.
    Palmer DH; Malagari K; Kulik LM
    J Hepatol; 2020 Feb; 72(2):277-287. PubMed ID: 31954492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and Transarterial therapy of HCC: What the interventional radiologist needs to know about the changing landscape of HCC treatment?
    Tibballs J; Clements W
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):478-482. PubMed ID: 35357076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma.
    Bai J; Huang M; Song B; Luo W; Ding R
    Technol Cancer Res Treat; 2023; 22():15330338231159718. PubMed ID: 36855803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.
    Brandi N; Renzulli M
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
    Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
    BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.
    Lygidakis NJ; Kosmidis P; Ziras N; Parissis J; Kyparidou E
    J Interferon Cytokine Res; 1995 May; 15(5):467-72. PubMed ID: 7544232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver-directed therapy for hepatocellular carcinoma.
    Narsinh KH; Duncan DP; Newton IG; Minocha J; Rose SC
    Abdom Radiol (NY); 2018 Jan; 43(1):203-217. PubMed ID: 29230556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape.
    Young S; Hannallah J; Goldberg D; Sanghvi T; Arshad J; Scott A; Woodhead G
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontiers of therapy for hepatocellular carcinoma.
    Heller M; Parikh ND; Fidelman N; Owen D
    Abdom Radiol (NY); 2021 Aug; 46(8):3648-3659. PubMed ID: 33837453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?
    Boilève J; Guimas V; David A; Bailly C; Touchefeu Y
    Curr Oncol; 2024 May; 31(6):3199-3211. PubMed ID: 38920726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
    Choi JY
    Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventional radiological treatment of hepatocellular carcinoma.
    Davis CR
    Cancer Control; 2010 Apr; 17(2):87-99. PubMed ID: 20404792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventional radiology meets immuno-oncology for hepatocellular carcinoma.
    Salem R; Greten TF
    J Hepatol; 2024 Jun; 80(6):967-976. PubMed ID: 35988688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review.
    Alnammi M; Wortman J; Therrien J; Afnan J
    Abdom Radiol (NY); 2022 Jul; 47(7):2299-2313. PubMed ID: 35524803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?
    Rizzo A
    Future Oncol; 2022 May; 18(14):1665-1668. PubMed ID: 35193371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.